Primary Analysis Of The Randomized Phase Ii Trial Of Bortezomib, Lenalidomide, Dexamthasone With/Without Elotuzumab For Newly Diagnosed, High-Risk Multiple Myeloma (Swog-1211).

Saad Zafar Usmani,Sikander Ailawadhi,Rachael Sexton,Antje Hoering,Brea Lipe,Sandi Hita,Brian G. Durie,Jeffrey A. Zonder,Madhav V. Dhodapkar,Natalie Scott Callander,S. Vincent Rajkumar,Peter Michael Voorhees,Paul G. Richardson,Robert Z. Orlowski

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 30|浏览33

暂无评分

摘要

8507Background: The introduction of immunomodulatory agents, proteasome inhibitors, and autologous stem cell transplantation (ASCT) has improved outcomes for patients with multiple myeloma (MM), bu...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要